You are here

  • Home
  • Archive
  • Volume 18, Issue 1
  • The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices

Article Text

Article menu
Download PDFPDF
Aetiology
Cohort study
The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices
  1. Laura E Targownik
  1. Department of Internal Medicine/Gastroenterology, University of Manitoba, Winnipeg, Canada
  1. Correspondence to Laura E Targownik
    805G-715 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E 3P4 Laura.Targownik{at}med.umanitoba.ca

https://doi.org/10.1136/ebmed-2012-100650

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Context

    There are currently over a dozen published manuscripts evaluating the relationship between proton pump inhibitors (PPIs) and the occurrence of osteoporotic fractures, in particular, fractures of the hip.1 In the majority of instances, a modest yet significant association between PPI use and hip fracture was detected. However, many of the previous studies were not able to control for potentially relevant confounders, including dietary intake of calcium and vitamin D, smoking and alcohol use, body mass index (BMI) and level of physical activity.

    Methods

    Khalili et al detail their analysis of 79 899 postmenopausal female participants from the Nurses' Health Study. In this dataset, women were interviewed regarding medical illness, use of medications (including PPIs from 2000 onwards), diet and level of physical activity. Cox proportional hazards models were constructed controlling for age, BMI, calcium and vitamin D intake, smoking, alcohol use, physical activity and …

    View Full Text

    Footnotes

    • Competing interests In the last 2 years, I have been on Advisory Boards for Merck Canada and Janssen Canada. I have been on a Speakers Panel for Pfizer Canada.